Back to Search
Start Over
Anti-Proliferative Effects of Lidocaine as an Autophagy Inducer in Bladder Cancer via Intravesical Instillation: In Vitro and Xenograft Mouse Model Experiments.
- Source :
- Cancers; Apr2024, Vol. 16 Issue 7, p1267, 12p
- Publication Year :
- 2024
-
Abstract
- Simple Summary: Our in vitro and in vivo experiments demonstrated that bladder tumor growth can be attenuated even with the intravesical administration of lidocaine as a single agent, and that the mechanism involves autophagy influx. These findings support the potential of intravesical lidocaine injection for clinical application. Further successful validation using human-derived bladder cancer cell lines and confirmation of the effectiveness of intravesical lidocaine administration in patients in clinical trials could help establish lidocaine as a novel adjuvant treatment for bladder cancer. Lidocaine exerts potential anti-tumor effects on various cancer cell lines, and its intravesical instillation is considered safer than intravenous administration for bladder cancer. However, the mechanisms underlying its anti-tumor effects have not been fully elucidated. Here, we aimed to elucidate the anti-tumor molecular mechanisms of lidocaine in bladder cancer cells and a xenograft model to substantiate the efficacy of its intravesical administration. We investigated the anti-proliferative and autophagyinducing activities of lidocaine in Nara Bladder Tumor No. 2 (NBT-II) rat bladder carcinoma cells using cell viability, flow cytometry, a wound healing assay, and western blotting. We also established a xenograft mouse model of bladder cancer, and cancer growth was examined using in vivo bioluminescence imaging. Lidocaine decreased cell viability, induced G0/G1 phase cell cycle arrest, and inhibited cell migration partially via glycogen synthase kinase (GSK) 3β phosphorylation. Moreover, a combination of lidocaine and SB216763 (a GSK3β inhibitor) suppressed autophagy-related protein expression. Bafilomycin-A1 with lidocaine significantly enhanced microtubule-associated protein 1A/1B-light chain (LC3B) expression; however, it decreased LC3B expression in combination with 3-methyladenine compared to lidocaine alone. In the xenograft mouse model, the bladder cancer volume was reduced by lidocaine. Overall, lidocaine exerts anti-proliferative effects on bladder cancer via an autophagy-inducing mechanism. [ABSTRACT FROM AUTHOR]
- Subjects :
- BLADDER tumors
BIOLOGICAL models
IN vitro studies
FLOW cytometry
WOUND healing
AUTOPHAGY
INTRAVESICAL administration
PHOSPHORYLATION
T-test (Statistics)
DATA analysis
RESEARCH funding
ANTINEOPLASTIC agents
CELL proliferation
DRUG administration
XENOGRAFTS
CELL cycle
TUMOR markers
CANCER patients
REVERSE transcriptase polymerase chain reaction
IN vivo studies
DESCRIPTIVE statistics
CELL lines
MICE
LUMINESCENCE spectroscopy
GENE expression
ANIMAL experimentation
WESTERN immunoblotting
ONE-way analysis of variance
STATISTICS
CELL survival
DATA analysis software
LIDOCAINE
PHARMACODYNAMICS
Subjects
Details
- Language :
- English
- ISSN :
- 20726694
- Volume :
- 16
- Issue :
- 7
- Database :
- Complementary Index
- Journal :
- Cancers
- Publication Type :
- Academic Journal
- Accession number :
- 176597912
- Full Text :
- https://doi.org/10.3390/cancers16071267